237 related articles for article (PubMed ID: 25115702)
1. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.
Wei SJ; Joseph T; Chee S; Li L; Yurlova L; Zolghadr K; Brown C; Lane D; Verma C; Ghadessy F
PLoS One; 2013; 8(11):e81068. PubMed ID: 24278380
[TBL] [Abstract][Full Text] [Related]
3. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.
Anil B; Riedinger C; Endicott JA; Noble ME
Acta Crystallogr D Biol Crystallogr; 2013 Aug; 69(Pt 8):1358-66. PubMed ID: 23897459
[TBL] [Abstract][Full Text] [Related]
4. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
[TBL] [Abstract][Full Text] [Related]
5. Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry.
Hernychova L; Man P; Verma C; Nicholson J; Sharma CA; Ruckova E; Teo JY; Ball K; Vojtesek B; Hupp TR
Proteomics; 2013 Aug; 13(16):2512-25. PubMed ID: 23776060
[TBL] [Abstract][Full Text] [Related]
6. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
7. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
8. Structure of the stapled p53 peptide bound to Mdm2.
Baek S; Kutchukian PS; Verdine GL; Huber R; Holak TA; Lee KW; Popowicz GM
J Am Chem Soc; 2012 Jan; 134(1):103-6. PubMed ID: 22148351
[TBL] [Abstract][Full Text] [Related]
9. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R
J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
[TBL] [Abstract][Full Text] [Related]
11. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
Nietzold F; Rubner S; Berg T
Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
[TBL] [Abstract][Full Text] [Related]
12. On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein.
ElSawy KM; Verma CS; Lane DP; Caves LS
Cell Cycle; 2013 Dec; 12(24):3727-35. PubMed ID: 24270847
[TBL] [Abstract][Full Text] [Related]
13. Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions.
Ricardo MG; Ali AM; Plewka J; Surmiak E; Labuzek B; Neochoritis CG; Atmaj J; Skalniak L; Zhang R; Holak TA; Groves M; Rivera DG; Dömling A
Angew Chem Int Ed Engl; 2020 Mar; 59(13):5235-5241. PubMed ID: 31944488
[TBL] [Abstract][Full Text] [Related]
14. In vitro selection of mutant HDM2 resistant to Nutlin inhibition.
Wei SJ; Joseph T; Sim AY; Yurlova L; Zolghadr K; Lane D; Verma C; Ghadessy F
PLoS One; 2013; 8(4):e62564. PubMed ID: 23653682
[TBL] [Abstract][Full Text] [Related]
15. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins.
Ha JH; Won EY; Shin JS; Jang M; Ryu KS; Bae KH; Park SG; Park BC; Yoon HS; Chi SW
J Am Chem Soc; 2011 Feb; 133(5):1244-7. PubMed ID: 21210687
[TBL] [Abstract][Full Text] [Related]
16. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
17. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
18. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
19. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
20. Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.
Wei SJ; Chee S; Yurlova L; Lane D; Verma C; Brown C; Ghadessy F
Oncotarget; 2016 May; 7(22):32232-46. PubMed ID: 27057630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
